Jonathan Zalevsky insider trades: Nektar Therapeutics (NKTR) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jonathan reports to the SEC
Open-market buys and sales
36 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | NKTR | ↓ Sell | 186 | $71.98 | $13K | Direct | Aug 20, 2026 (2d) |
| Jun 30, 2026 | NKTR | ↓ Sell | 5,681 | $70.00 | $398K | Direct | Jul 2, 2026 (2d) |
| Jun 15, 2026 | NKTR | ↓ Sell | 5,538 | $60.71 | $336K | Direct | Jun 17, 2026 (2d) |
| May 19, 2026 | NKTR | ↓ Sell | 199 | $65.51 | $13K | Direct | May 21, 2026 (2d) |
| Feb 18, 2026 | NKTR | ↓ Sell | 180 | $73.00 | $13K | Direct | Feb 20, 2026 (2d) |
| Jan 20, 2026 | NKTR | ↓ Sell | 3,867 | $35.67 | $138K | Direct | Jan 22, 2026 (2d) |
| Nov 25, 2025 | NKTR | ↓ Sell | 1,157 | $54.28 | $63K | Direct | Nov 25, 2025 (0d) |
| Sep 4, 2025 | NKTR | ↓ Sell | 1,721 | $33.52 | $58K | Direct | Sep 8, 2025 (4d) |
| Sep 2, 2025 | NKTR | ↓ Sell | 485 | $30.10 | $15K | Direct | Sep 4, 2025 (2d) |
| Aug 19, 2025 | NKTR | ↓ Sell | 725 | $26.59 | $19K | Direct | Aug 21, 2025 (2d) |
| May 19, 2025 | NKTR | ↓ Sell | 10,712 | $0.67 | $7K | Direct | May 21, 2025 (2d) |
| Feb 19, 2025 | NKTR | ↓ Sell | 10,300 | $1.01 | $10K | Direct | Feb 21, 2025 (2d) |
| Dec 19, 2024 | NKTR | ↓ Sell | 51,115 | $0.94 | $48K | Direct | Dec 20, 2024 (1d) |
| Nov 19, 2024 | NKTR | ↓ Sell | 7,785 | $1.01 | $8K | Direct | Nov 20, 2024 (1d) |
| Aug 19, 2024 | NKTR | ↓ Sell | 6,866 | $1.28 | $9K | Direct | Aug 20, 2024 (1d) |
| May 17, 2024 | NKTR | ↓ Sell | 7,355 | $1.75 | $13K | Direct | May 20, 2024 (3d) |
| Feb 20, 2024 | NKTR | ↓ Sell | 9,014 | $0.68 | $6K | Direct | Feb 22, 2024 (2d) |
| Nov 17, 2023 | NKTR | ↓ Sell | 9,646 | $0.49 | $5K | Direct | Nov 20, 2023 (3d) |
| Aug 16, 2023 | NKTR | ↓ Sell | 9,703 | $0.78 | $8K | Direct | Aug 17, 2023 (1d) |
| May 16, 2023 | NKTR | ↓ Sell | 9,791 | $0.72 | $7K | Direct | May 17, 2023 (1d) |
| Feb 16, 2023 | NKTR | ↓ Sell | 10,484 | $3.00 | $31K | Direct | Feb 17, 2023 (1d) |
| Nov 16, 2022 | NKTR | ↓ Sell | 13,460 | $3.57 | $48K | Direct | Nov 18, 2022 (2d) |
| Aug 18, 2022 | NKTR | ↓ Sell | 73,716 | $4.65 | $343K | Direct | Aug 19, 2022 (1d) |
| Aug 16, 2022 | NKTR | ↓ Sell | 10,560 | $4.76 | $50K | Direct | Aug 17, 2022 (1d) |
| May 16, 2022 | NKTR | ↓ Sell | 21,673 | $3.95 | $86K | Direct | May 17, 2022 (1d) |
| Feb 16, 2022 | NKTR | ↓ Sell | 10,912 | $10.95 | $119K | Direct | Feb 18, 2022 (2d) |
| Nov 16, 2021 | NKTR | ↓ Sell | 20,869 | $13.16 | $275K | Direct | Nov 17, 2021 (1d) |
| Aug 16, 2021 | NKTR | ↓ Sell | 7,662 | $13.83 | $106K | Direct | Aug 18, 2021 (2d) |
| May 17, 2021 | NKTR | ↓ Sell | 31,111 | $18.30 | $569K | Direct | May 19, 2021 (2d) |
| Feb 16, 2021 | NKTR | ↓ Sell | 24,141 | $22.37 | $540K | Direct | Feb 18, 2021 (2d) |
| Nov 23, 2020 | NKTR | ↓ Sell | 16,380 | $16.40 | $269K | Direct | Nov 25, 2020 (2d) |
| Nov 16, 2020 | NKTR | ↓ Sell | 29,618 | $16.93 | $501K | Direct | Nov 18, 2020 (2d) |
| Aug 17, 2020 | NKTR | ↓ Sell | 26,200 | $19.67 | $515K | Direct | Aug 19, 2020 (2d) |
| May 18, 2020 | NKTR | ↓ Sell | 4,558 | $22.51 | $103K | Direct | May 20, 2020 (2d) |
| Feb 18, 2020 | NKTR | ↓ Sell | 4,774 | $22.35 | $107K | Direct | Feb 20, 2020 (2d) |
| Nov 18, 2019 | NKTR | ↓ Sell | 3,960 | $17.97 | $71K | Direct | Nov 20, 2019 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NKTR insiders
Open-market trades in the last 12 months
About Jonathan Zalevsky's insider trades
Jonathan Zalevsky is Chief R&D Officer at Nektar Therapeutics (NKTR). Since Nov 18, 2019, Jonathan has reported no open-market purchases and 36 sales worth $4.9M on SEC Form 4. In the last 12 months: 7 sales ($974K).
Their filings also include grants and awards (14 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NKTR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.